In Silico Mapping of Essential Residues in the Catalytic Domain of PDE5 Responsible for Stabilization of Its Commercial Inhibitors

Autor(es)

de Oliveira, Ivan Pires ^[1] ; Lescano, Caroline Honaiser ^[2] ; De Nucci, Gilberto ^{[1, 2]}

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Inst Biomed Sci, Dept Pharmacol, BR-05508900 Sao Paulo, SP - Brazil

^[2] Univ Estadual Campinas, Sch Med Sci, Dept Pharmacol, BR-13083887 Campinas, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: SCIENTIA PHARMACEUTICA; v. 87, n. 4 DEC 2019.
• Citações Web of Science: 0

Resumo

Phosphodiesterase type 5 (PDE5) is an important enzyme associated with the hydrolysis of cyclic guanosine monophosphate (cGMP) to guanosine monophosphate (GMP). Due to the relevant role of second messenger cGMP as a mediator in many physiological processes, efforts have been converged to find a safe pharmacological approach, seeking a specific, selective and potent inhibitor of the PDE5 enzyme. There are five commercial drugs with potential for clinical use: tadalafil, sildenafil, avanafil, udenafil and vardenafil. Here, we applied molecular modeling to obtain different profiles of protein-ligand interactions by adopting distinct PDE5 structures, specifically PDBid:1XOZ and two extracted from molecular dynamics (MD) simulations. The results generated by molecular docking showed several possibilities for inhibitor interactions with the catalytic pocket. Tadalafil, sildenafil and vardenafil were clearly stabilized by Gln817 via a well-oriented hydrogen bond. Another set of different interactions, such as polar, hydrophobic, pi-stacking, metal-ligand and electrostatic, were responsible for accommodating avanafil and udenafil. All of the ligands are discussed in detail with consideration of the distinct protein structures, and a profile of the probability of residue-ligand contact is suggested, with the most frequently observed being: Tyr612, His613, Ser661, Thr723, Asp724, Asp764, Leu765, Val782 and Phe786. The molecular interactions displayed herein confirm findings achieved by previous authors and also present new contacts. In addition, the discussion can help researchers obtain a molecular basis for planning new selective PDE5 inhibitors, as well as explain an inhibitor's experimental assays by considering the specific interactions occurring at the catalytic site. (AU)

• Processo FAPESP: 13/22360-9 - Estudo computacional do mecanismo de conversão de ATP a AMP-cíclico catalisada pelo Fator de Edema do Antraz
• Beneficiário: Gabriel Ernesto Jara
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 10/16947-9 - Estrutura, dinâmica e função em proteínas: simulação computacional e desenvolvimento de algoritmos
• Beneficiário: Leandro Martinez
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 13/08293-7 - CECC - Centro de Engenharia e Ciências Computacionais
• Beneficiário: Munir Salomao Skaf
• Modalidade de apoio: Auxílio à Pesquisa - Centros de Pesquisa, Inovação e Difusão - CEPIDs
• Processo FAPESP: 13/05475-7 - Métodos computacionais de otimização
• Beneficiário: Sandra Augusta Santos
• Modalidade de apoio: Auxílio à Pesquisa - Temático
• Processo FAPESP: 17/02201-4 - Estudo da inibição do acúmulo de nucleotídeos cíclicos por derivados de piridopirimidinas usando simulações de dinâmica molecular
• Beneficiário: Ivan Pires de Oliveira
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 17/26687-3 - Caracterização farmacológica das gliflozinas em plaquetas humanas isoladas: avaliação in vitro, in vivo e modelagem molecular
• Beneficiário: Caroline Honaiser Lescano
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado